Brexit

Brexit—key steps, concepts and timeline

By way of background, Practice Note: Brexit—exiting the EU under Article 50 [Archived] explains the operation of the withdrawal process under Article 50 of the Treaty on European Union and considers some of the key issues and the consequences arising in the context of the UK becoming the first EU Member State to withdraw its membership.

Our Brexit legislation tracker records the progress of UK legislation introduced as part of the legislative project associated with the UK’s withdrawal from the EU. Also see: Brexit legislation tracker 2017–19 [Archived], which tracked the progress of primary legislation introduced as part of the legislative preparation for the UK’s withdrawal from the EU during the 2017–19 Parliament.

From the point of its exit from the EU (31 January 2020), the UK’s relationship with the EU was governed by the Withdrawal Agreement, an international treaty negotiated by the UK and the EU during the withdrawal period, which was introduced to:

  1. tie up the administrative and financial loose ends associated with the UK’s membership of the EU

  2. protect the rights of UK and EU citizens living in each

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

Life Sciences weekly highlights—12 February 2026

This week's edition of Life Sciences weekly highlights includes analysis of the Supreme Court’s decision in Emotional Perception AI Ltd v Comptroller-General of Patents, Designs and Trade Marks, in which the court held that an artificial neural network system is not excluded from patentability as a ‘program for a computer…as such’, aligning UK law more closely with European Patent Office jurisprudence. Also included, is news that the DHSC has opened a consultation on changes to the statutory scheme for branded medicines pricing to align with the voluntary scheme, DHSC also released its finding and recommendations on the operation of the Medicines and Medical Devices Act 2021 in its five-year report and it has also opened a consultation on proposed amendments to strengthen medicines reimbursement, supply oversight and compliance further to its 2025 annual review of the Health Service Products 2018 regulations. Further developments include NICE launching the National HealthTech Access Programme, MHRA updating its pharmacovigilance requirements for UK authorised products further to Commission Implementing Regulation (EU) 520/2012 (CIR 520/2012), the Notified Bodies industry publishing a letter addressing proposed cybersecurity amendments to the medical devices regulations, the adoption of the international standards ICH M15 guideline for model-informed drug development, the EMA launching a consultation on making Annex 15 GMP qualification and validation guidelines mandatory, and the EFPIA published proposals to strengthen EU pharmaceutical competitiveness, among other stories.

View Life Sciences by content type :

Popular documents